Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Tokat UM, Ulukan B, Cetin M, Calisir K, Gedik ME, Bal H, Sener Sahin O, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O.
Saatci O, et al. Among authors: ulukan b.
Cell Death Dis. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3.
Cell Death Dis. 2024.
PMID: 38879508
Free PMC article.